Health care technology can be a cure for ailing portfolios

November 2, 2020

By The Globe and Mail – October 13, 2020

This content was produced by the Globe Content Studio.

Health care technology can be a cure for ailing portfolios

 

Immunotherapies and robotic-assisted surgeries hold promise

The doctor will see you now wherever you happen to be. Telemedicine has existed for years, but in mere months, COVID-19 has moved the technology from the margins of health care to standard operating procedure.

“We are seeing a lot more medical care being delivered digitally, which has been promised for a long time and just got accelerated [by the pandemic],” said Walter Wodchis, a professor at the University of Toronto’s Institute of Health Policy, Management and Evaluation. 

Advancements in telemedicine and other technology, which are making delivery of health care more efficient and productive, should quicken investors’ pulse, he says. 

Earlier this year, Deloitte published a health tech investment trends report, which forecasts an increase in spending on health care delivery technology to the point that “by 2040, health care as we know it today, will no longer exist.”

That was in March. Since then, Peter Micca, one of the report’s authors and a partner in Deloitte’s life sciences and health care division, says, “Our proposition of the future of health has accelerated, and we believe that many of the changes that we were contemplating will likely occur much more quickly.” 

Health care can be a cure for ailing portfolios, providing tremendous opportunities for growth thanks partly to technological advances in medical science. In these uncertain times, the health sector is also largely recession-resistant. Because of its nature, it’s less sensitive to the economic cycle and contains a diverse range of products and services.  

But what holds the most promise as the next big thing? Paul MacDonald, chief investment officer at Harvest ETFs, recommends focusing on two areas in which innovation is exploding. One is in immunotherapies, which are drugs that effectively use your own immune system to target various diseases. And in the medical device space, robotic-assisted surgeries are at the forefront. 

For Mr. Micca, telemedicine remains intriguing. Two reasons for its rise this year are the removal of regulatory barriers to allow physicians to treat across jurisdictions and reimbursements for telemedicine visits at a reasonable rate. It’s unlikely that we’ll return to the status quo, he says. “The barn door is open. It is going to be virtually impossible, I think, to roll back the changes that have occurred.”

Greg Button, president of global health care services at organizational consultancy Korn Ferry, says investors looking for the shortest-term gains should seek out the largest players already in the health care tech space. Pick them over new entrants, no matter how well funded the latter might be, he advises.

“There are some cutting edge companies that are just too far ahead of the market,” Mr. Button says.  

For example, some advances tie into the shift in models from fee-for-service to outcomes-based or values-based care. That relies on data and might make sense, but the investment thesis “is a tricky one,” Mr. Button says. “Delivery of care is different from investing in some new drug or biotech company.”

Health care is one of the sectors being transformed the most by the “internet of things,” the phrase used to describe the interconnection of sensors and software with any number of devices.

The advances, from connected pacemakers to virtual visits, are unfolding rapidly. One way to reduce risk and capture the opportunities is to invest in global leaders that have proven businesses and the resources for research and development.

For example, Harvest Healthcare Leaders Income ETF holds 20 global companies with an average market capitalization of more than $200-billion. The biggest weightings are pharmaceuticals and health care equipment and supplies.

Investors looking for a less complicated and more profitable entry point should seek mutual funds and exchange-traded funds focused on health care technology, Mr. MacDonald says.

“My overriding message would be, ‘Don’t try to find the needle in the haystack. Instead, just own the haystack,’” Mr. MacDonald says. “Then, you can participate in the sector’s overall growth.”

 

*Harvest ETFs are managed by Harvest Portfolios Group Inc.

You may also like…

Disclaimer

You will usually pay brokerage fees to your dealer if you purchase or sell units of the Fund(s) on the TSX. If the units are purchased or sold on the TSX, investors may pay more than the current net asset value when buying units of the Fund(s) and may receive less than the current net asset value when selling them. There are ongoing fees and expenses associated with owning units of an investment fund. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the fund in these documents.

Certain statements in the Harvest Blog are forward looking Forward-looking statements (“FLS”) are statements that are predictive in nature, depend upon or refer to future events or conditions, or that include words such as “may,” “will,” “should,” “could,” “expect,” “anticipate,” “intend,” “plan,” “believe,” or  “estimate,” or other similar expressions. Statements that look forward in time or include anything other than historical information are subject to risks and uncertainties, and actual results, actions or events could differ materially from those set forth in the FLS.

FLS are not guarantees of future performance and are by their nature based on numerous assumptions, which include, amongst other things, that (i) the Fund can attract and maintain investors and have sufficient capital under management to effect their investment strategies, (ii) the investment strategies will produce the results intended by the portfolio managers, and (iii) the markets will react and perform in a manner consistent with the investment strategies. Although the FLS contained herein are based upon what the portfolio manager believe to be reasonable assumptions, the portfolio manager cannot assure that actual results will be consistent with these FLS.

Unless required by applicable law, Harvest Portfolios Group Inc. does not undertake, and specifically disclaim, any intention or obligation to update or revise any FLS, whether as a result of new information, future events or otherwise.

Subscribe to our newsletter and stay informed

Join Us & Stay Informed!

* indicates required

Your Preferences   (Please select all the ways you would like to hear from)


You are a *


Confirm *